Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boiron S.A. (BOI.PA)
Messimy, FR
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.43% | +2.16% | +3.65% | +3.65% | -0.35% | -6.27% | +17.60% | -26.33% | -31.40% | -62.71% | +294.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.8% Q4'25: +0.8% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+189.2% ★ Q4'25: +3.4% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+7.0% ★ Q4'25: +6.1% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.1% Q4'25: +7.8% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.0% ★ Q4'25: +18.2% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.1% Q4'25: +1.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.47× ★ Q4'25: 0.22× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 1998 actual |
Dec 1999 actual |
Dec 2000 actual |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
217.27M
est.
|
238.14M
est.
|
256.68M
est.
|
266.39M
est: 271.38M (-1.8%)
|
287.05M
est: 288.70M (-0.6%)
|
305.34M
est: 310.78M (-1.8%)
|
290.63M
est: 318.73M (-8.8%)
|
361.65M
est: 367.11M (-1.5%)
|
398.67M
est: 405.43M (-1.7%)
|
434.47M
est: 437.18M (-0.6%)
|
466.89M
est: 471.80M (-1.0%)
|
526.28M
est: 525.75M (+0.1%)
|
520.60M
est: 527.96M (-1.4%)
|
523.45M
est: 533.65M (-1.9%)
|
566.29M
est: 570.25M (-0.7%)
|
617.99M
est: 626.83M (-1.4%)
|
609.98M
est: 619.35M (-1.5%)
|
607.96M
est: 612.18M (-0.7%)
|
614.49M
est: 616.48M (-0.3%)
|
617.54M
est: 619.08M (-0.2%)
|
604.22M
est: 605.63M (-0.2%)
|
557.12M
est: 557.07M (+0.0%)
|
513.58M
est: 517.22M (-0.7%)
|
455.20M
est: 455.15M (+0.0%)
|
534.24M
est: 534.20M (+0.0%)
|
493.25M
est: 481.71M (+2.4%)
|
487.56M
est: 493.25M (-1.2%)
|
501.11M
est: 504.60M (-0.7%)
|
522.30M
522.30M – 522.30M
+3.5% YoY
|
540.60M
540.60M – 540.60M
+3.5% YoY
|
| EBITDA |
36.68M
est.
|
39.13M
est.
|
41.07M
est.
|
42.94M
est: 47.79M (-10.1%)
|
51.48M
est: 45.96M (+12.0%)
|
56.69M
est: 58.19M (-2.6%)
|
48.46M
est: 58.77M (-17.5%)
|
49.01M
est: 56.55M (-13.3%)
|
38.00M
est: 53.12M (-28.5%)
|
63.04M
est: 39.87M (+58.1%)
|
81.51M
est: 66.91M (+21.8%)
|
110.88M
est: 97.17M (+14.1%)
|
87.58M
est: 111.57M (-21.5%)
|
86.57M
est: 104.11M (-16.8%)
|
117.17M
est: 92.47M (+26.7%)
|
156.40M
est: 129.49M (+20.8%)
|
167.74M
est: 162.14M (+3.4%)
|
150.91M
est: 163.46M (-7.7%)
|
157.00M
est: 151.18M (+3.8%)
|
159.38M
est: 157.41M (+1.3%)
|
138.56M
est: 147.41M (-6.0%)
|
99.16M
est: 127.90M (-22.5%)
|
68.91M
est: 98.42M (-30.0%)
|
78.76M
est: 95.50M (-17.5%)
|
91.33M
est: 96.51M (-5.4%)
|
73.67M
est: 69.26M (+6.4%)
|
45.46M
est: 70.92M (-35.9%)
|
66.30M
est: 72.55M (-8.6%)
|
75.09M
75.09M – 75.09M
+3.5% YoY
|
77.72M
77.72M – 77.72M
+3.5% YoY
|
| EBIT |
30.39M
est.
|
31.79M
est.
|
34.81M
est.
|
31.36M
est: 31.51M (-0.5%)
|
36.84M
est: 34.25M (+7.6%)
|
39.52M
est: 42.08M (-6.1%)
|
33.90M
est: 40.51M (-16.3%)
|
25.31M
est: 41.81M (-39.5%)
|
19.62M
est: 27.17M (-27.8%)
|
45.40M
est: 20.80M (+118.3%)
|
56.98M
est: 48.24M (+18.1%)
|
90.38M
est: 63.74M (+41.8%)
|
67.10M
est: 92.19M (-27.2%)
|
67.69M
est: 67.42M (+0.4%)
|
84.03M
est: 67.55M (+24.4%)
|
146.03M
est: 89.15M (+63.8%)
|
146.11M
est: 132.70M (+10.1%)
|
135.18M
est: 147.20M (-8.2%)
|
133.92M
est: 125.53M (+6.7%)
|
130.01M
est: 131.06M (-0.8%)
|
108.40M
est: 120.94M (-10.4%)
|
63.21M
est: 97.84M (-35.4%)
|
36.30M
est: 64.50M (-43.7%)
|
45.38M
est: 62.59M (-27.5%)
|
59.50M
est: 63.26M (-5.9%)
|
48.04M
est: 39.54M (+21.5%)
|
15.24M
est: 51.32M (-70.3%)
|
35.40M
est: 41.41M (-14.5%)
|
42.87M
42.87M – 42.87M
+3.5% YoY
|
44.37M
44.37M – 44.37M
+3.5% YoY
|
| Net Income |
13.75M
est.
|
15.67M
est.
|
16.71M
est.
|
19.70M
est: 20.62M (-4.5%)
|
23.02M
est: 20.96M (+9.8%)
|
25.63M
est: 25.74M (-0.4%)
|
20.59M
est: 26.26M (-21.6%)
|
16.42M
est: 25.45M (-35.5%)
|
10.25M
est: 18.11M (-43.4%)
|
27.16M
est: 10.99M (+147.1%)
|
39.18M
est: 29.25M (+34.0%)
|
59.89M
est: 43.68M (+37.1%)
|
43.28M
est: 60.05M (-27.9%)
|
42.26M
est: 43.77M (-3.4%)
|
49.63M
est: 44.75M (+10.9%)
|
82.40M
est: 54.52M (+51.1%)
|
89.05M
est: 81.42M (+9.4%)
|
73.93M
est: 90.92M (-18.7%)
|
77.73M
est: 73.34M (+6.0%)
|
78.24M
est: 78.56M (-0.4%)
|
57.46M
est: 75.71M (-24.1%)
|
40.63M
est: 53.03M (-23.4%)
|
26.21M
est: 39.17M (-33.1%)
|
28.56M
est: 38.00M (-24.9%)
|
44.67M
est: 47.62M (-6.2%)
|
35.83M
est: 23.94M (+49.7%)
|
11.34M
est: 19.89M (-43.0%)
|
32.64M
est: 27.37M (+19.3%)
|
36.14M
36.14M – 36.14M
+32.1% YoY
|
37.37M
37.37M – 37.37M
+3.4% YoY
|
| SGA |
74.42M
est.
|
78.81M
est.
|
81.70M
est.
|
91.87M
est: 102.87M (-10.7%)
|
98.69M
est: 111.70M (-11.6%)
|
106.01M
est: 122.54M (-13.5%)
|
32.26M
est: 115.99M (-72.2%)
|
78.77M
est: 143.16M (-45.0%)
|
90.65M
est: 87.03M (+4.2%)
|
295.16M
est: 97.74M (+202.0%)
|
303.32M
est: 106.62M (+184.5%)
|
316.22M
est: 120.57M (+162.3%)
|
340.48M
est: 115.38M (+195.1%)
|
345.53M
est: 130.19M (+165.4%)
|
275.82M
est: 131.50M (+109.7%)
|
345.34M
est: 296.13M (+16.6%)
|
346.43M
est: 270.83M (+27.9%)
|
353.96M
est: 275.83M (+28.3%)
|
355.91M
est: 276.80M (+28.6%)
|
360.32M
est: 279.56M (+28.9%)
|
362.69M
est: 275.87M (+31.5%)
|
273.26M
est: 267.36M (+2.2%)
|
244.30M
est: 268.45M (-9.0%)
|
212.80M
est: 260.49M (-18.3%)
|
236.90M
est: 263.25M (-10.0%)
|
232.83M
est: 227.32M (+2.4%)
|
238.27M
est: 232.76M (+2.4%)
|
244.46M
est: 238.12M (+2.7%)
|
246.47M
246.47M – 246.47M
+3.5% YoY
|
255.11M
255.11M – 255.11M
+3.5% YoY
|
| EPS |
0.71
est.
|
0.78
est.
|
0.99
est.
|
1.06
est: 1.08 (-1.8%)
|
1.24
est: 1.17 (+5.6%)
|
1.38
est: 1.39 (-1.0%)
|
1.11
est: 1.24 (-10.3%)
|
0.81
est: 0.84 (-3.0%)
|
0.47
est: 0.58 (-19.2%)
|
1.25
est: 1.05 (+18.8%)
|
1.79
est: 1.62 (+10.6%)
|
2.78
est: 2.36 (+17.8%)
|
2.02
est: 1.98 (+1.8%)
|
1.97
est: 1.59 (+24.2%)
|
2.36
est: 2.50 (-5.7%)
|
4.24
est: 3.60 (+17.9%)
|
4.62
est: 4.15 (+11.4%)
|
4.01
est: 3.42 (+17.4%)
|
4.22
est: 3.35 (+26.2%)
|
4.25
est: 3.22 (+32.0%)
|
3.23
est: 3.01 (+7.3%)
|
2.32
est: 1.66 (+39.4%)
|
1.50
est: 0.63 (+137.9%)
|
1.63
est: 1.18 (+38.2%)
|
2.57
est: 2.12 (+21.5%)
|
2.06
est: 1.36 (+51.0%)
|
0.65
est: 1.13 (-42.7%)
|
1.88
est: 1.56 (+20.5%)
|
2.06
2.06 – 2.06
+32.1% YoY
|
2.13
2.13 – 2.13
+3.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 20.0K | 0.30% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 72.1K | 0.28% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 32.0K | 0.22% |
| 4 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
| 5 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | — | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thierry Boiron | Deputy GM & Director | 455.3K | male |
| Fabrice Rey | Group Treasurer | — | male |
| Gregoire Balay | Marketing Director | — | — |
| Julien Navarra | Legal Director | — | — |
| Eric Lambert | Secretary General | — | male |
| Pascal Houdayer | GM & Director | — | male |
| Patrice Varraut | Director of Operations | — | male |
| Juliette Baudry | Human Resources Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BOI.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
